1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Comorbidity between borderline personality disorder (BPD) and alcohol use disorder (AUD) is high and relevant as alcohol consumption seems to worsen BPD symptomatology. One of the newest treatments for AUD, nalmefene, may be useful to improve BPD symptoms not only indirectly by reducing alcohol consumption but also directly by acting on the opioid system as this system has been related to specific BPD symptoms. This open-label study aimed at evaluating the efficacy of an 8-week nalmefene treatment in reducing alcohol consumption in individuals with BPD and comorbid AUD. A secondary objective was to assess its efficacy in improving general BPD symptomatology and specific behaviors (self injury and binge eating). Eighteen out of the 25 patients with BPD and comorbid AUD enrolled in the study completed all the assessment points. After 8 weeks, a significant reduction was observed in alcohol consumption, BPD global symptomatology, self-injurious behavior, and binge eating. No serious adverse effects were reported; however, five participants experienced mild side effects, resulting in withdrawal from the study in two cases. According to our results, nalmefene may be a safe and effective drug for treating patients with BPD and comorbid AUD. Controlled clinical trials are needed to support our findings.

          Related collections

          Author and article information

          Journal
          Int Clin Psychopharmacol
          International clinical psychopharmacology
          Ovid Technologies (Wolters Kluwer Health)
          1473-5857
          0268-1315
          July 2017
          : 32
          : 4
          Affiliations
          [1 ] aDepartment of Psychiatry, Santa Creu and Sant Pau Hospital, Research Institute of the Santa Creu and Sant Pau Hospital (IIB Sant Pau), Barcelona (Spain), Autonomous University of Barcelona, CIBER of Mental Health (CIBERSAM) bBorderline Personality Disorder Unit, General Hospital of Catalonia, Sant Cugat, Spain.
          Article
          10.1097/YIC.0000000000000170
          28181957
          d1617537-60ff-4e7e-900c-2d3288cbbeb7
          History

          Comments

          Comment on this article